understanding the RSV Threat

Respiratory Syncytial Virus (RSV) is a ubiquitous respiratory pathogen, responsible for a substantial burden of illness across all age groups.However, the virus poses the greatest risk to two distinct populations: infants and older adults. Prior to the development of these vaccines, RSV was a leading cause of bronchiolitis and pneumonia in children under one year of age, and a significant contributor to serious respiratory illness and hospitalization in adults 65 years and older. the fall and winter months typically see a surge in RSV cases, overwhelming healthcare systems.

Historically, managing RSV has been largely supportive, focusing on hydration and respiratory support. While treatments like ribavirin exist, thier use is limited due to side effects and efficacy concerns. Palivizumab, a monoclonal antibody, is available for high-risk infants, but is expensive and requires monthly governance.

The Landmark Vaccine Approvals

On May 3, 2023, the Food and Drug Administration (FDA) approved the first RSV vaccines, marking a pivotal moment in preventative medicine. Two vaccines were authorized: Arexvy, developed by GSK, and Abrysvo, from Pfizer. These vaccines utilize different technologies – Arexvy employs a recombinant subunit vaccine approach, while Abrysvo utilizes a bivalent mRNA vaccine. Both target the RSV-A strain, which is responsible for the majority of severe RSV infections.

The approval was based on robust clinical trial data demonstrating significant efficacy in preventing LRTD. The trials, conducted across multiple sites and involving tens of thousands of participants, consistently showed a reduction in RSV-related hospitalizations and severe illness.

Real-World Impact: Data from October 2025

Data published on October 23, 2025, in the new England Journal of Medicine provides compelling evidence of the vaccines’ effectiveness in real-world settings. A large-scale observational study,encompassing over 500,000 vaccinated individuals aged 60 and older,revealed a 60-70% reduction in RSV-associated hospitalizations during the 2024-2025 RSV season. This translates to a substantial decrease in healthcare burden and improved outcomes for vulnerable populations.

Moreover, analysis of infant vaccination rates and RSV incidence showed a marked decline in RSV-related hospitalizations among infants whose mothers received the Abrysvo vaccine during pregnancy. Maternal vaccination provides passive immunity to the infant, offering protection during the first few months of life, a period when they are most vulnerable.

Who Should Get Vaccinated?

The Centers for Disease